Makscientific
MAKScientific is a Boston-based pharmaceutical company that is dedicated to developing drugs targeting the endocannabinoid system to treat various medical disorders. With a focus on selective targeting of components such as cannabinoid receptors and enzymes, they have a growing portfolio of small molecule modulators that have shown promise in animal models of human disease.
One of their advanced drug candidates, AM6545, is a peripherally restricted CB1 receptor antagonist that offers a potential new approach to managing chronic liver disease and metabolic disorders. Seeking a partner for further development and commercialization, MAKScientific has already advanced this drug candidate to the late pre-clinical stage with no adverse pre-clinical data to date.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.